{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T15:51:21Z","timestamp":1789314681776,"version":"build-2803163510"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010544","name":"Exelixis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.clgc.2019.11.012","type":"journal-article","created":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T22:49:09Z","timestamp":1575499749000},"page":"429-435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non\u2013Clear Cell Renal Cell Carcinoma"],"prefix":"10.1016","volume":"18","author":[{"given":"Ruby","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe Chaim","family":"Ornstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly D.","family":"Allman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura S.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Gilligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge A.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dendra Von","family":"Merveldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J.","family":"Hammers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian I.","family":"Rini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2019.11.012_bib1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clgc.2019.11.012_bib2","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2019.11.012_bib3","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.11.012_bib4","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.11.012_bib5","author":"Albiges"},{"key":"10.1016\/j.clgc.2019.11.012_bib6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs\u2014part A: renal, penile, and testicular tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.11.012_bib7","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2014.05.010","article-title":"Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis","volume":"67","author":"Vera-Badillo","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.11.012_bib8","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1002\/cncr.28151","article-title":"Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC database consortium criteria","volume":"119","author":"Kroeger","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2019.11.012_bib9","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1470-2045(15)00515-X","article-title":"Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial","volume":"17","author":"Armstrong","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2019.11.012_bib10","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.eururo.2015.10.049","article-title":"Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial","volume":"69","author":"Tannir","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.11.012_bib11","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/annonc\/mdx075","article-title":"Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC","volume":"28","author":"Knox","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2019.11.012_bib12","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1093\/annonc\/mdu445","article-title":"PD-L1 expression in nonclear-cell renal cell carcinoma","volume":"25","author":"Choueiri","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2019.11.012_bib13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40425-018-0319-9","article-title":"Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma","volume":"6","author":"Koshkin","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"issue":"suppl","key":"10.1016\/j.clgc.2019.11.012_bib14","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2019.37.7_suppl.547","article-title":"Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab+ ipilimumab (N+ I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)","volume":"37","author":"Tannir","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.11.012_bib15","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1158\/2326-6066.CIR-17-0475","article-title":"The clinical activity of PD-1\/PD-L1 inhibitors in metastatic non-clear cell renal cell carcinoma","volume":"6","author":"McKay","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.clgc.2019.11.012_bib16","author":"Chahoud"},{"issue":"suppl","key":"10.1016\/j.clgc.2019.11.012_bib17","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1200\/JCO.2019.37.7_suppl.546","article-title":"First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): results from KEYNOTE-427 cohort B","volume":"37","author":"McDermott","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.clgc.2019.11.012_bib18","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1200\/JCO.2019.37.7_suppl.545","article-title":"A\u00a0phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO)","volume":"37","author":"Powles","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.clgc.2019.11.012_bib19","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.1200\/JCO.2019.37.15_suppl.4583","article-title":"Atezolizumab plus bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (ccRCCsd): updated results of activity and predictive biomarkers from a phase II study","volume":"37","author":"Flippot","year":"2019","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319303635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319303635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:33:07Z","timestamp":1761564787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767319303635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1558767319303635"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2019.11.012","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non\u2013Clear Cell Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2019.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}